Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

Naval Daver, Aditi Shastri, Tapan Kadia, Alfonso Quintas-Cardama, Elias Jabbour, Marina Konopleva, Susan O'Brien, Sherry Pierce, Lingsha Zhou, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0. mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5. mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.

Original languageEnglish (US)
Pages (from-to)1440-1444
Number of pages5
JournalLeukemia Research
Volume37
Issue number11
DOIs
StatePublished - Nov 1 2013
Externally publishedYes

Keywords

  • Anemia
  • Myelofibrosis
  • Pomalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Modest activity of pomalidomide in patients with myelofibrosis and significant anemia'. Together they form a unique fingerprint.

  • Cite this

    Daver, N., Shastri, A., Kadia, T., Quintas-Cardama, A., Jabbour, E., Konopleva, M., O'Brien, S., Pierce, S., Zhou, L., Cortes, J., Kantarjian, H., & Verstovsek, S. (2013). Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leukemia Research, 37(11), 1440-1444. https://doi.org/10.1016/j.leukres.2013.07.007